✦ LIBER ✦

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

✍ Scribed by Goldhirsch, Aron; Gelber, Richard D; Piccart-Gebhart, Martine J; de Azambuja, Evandro; Procter, Marion; Suter, Thomas M; Jackisch, Christian; Cameron, David; Weber, Harald A; Heinzmann, Dominik; Lago, Lissandra Dal; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; Otero-Reyes, Douglas; Song, Santai; Smith, Ian; Leyland-Jones, Brian; Baselga, Jose

Book ID: 120605209
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 449 KB
Volume: 382
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(13)61094-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2-year follow-up of trastuzumab after ad

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

✍ Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyerei 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB

Treatment with trastuzumab for 1 year af

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

✍ Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbaue 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 322 KB

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

✍ José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambu 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 320 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

## Background: Patients with progressive disease after two or more her2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. we aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent dm1 linked to trastuzumab,

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUV

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

✍ T.T.T. Nguyen; R. Yagudina; A.U. Kulikov 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB